Erik Lundgren was named Chief Executive Officer of Immunic, Inc. As of November 6, 2026, Immunic, Inc. has reported 8 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 31, 2026 to September 11, 2026, naming 5 appointments and 3 departures (Form 8-K, May 27, 2026).
IMMUNIC, INC. announced the departure of its Director on Sep 11. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Immunic, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Duane Nash · Role: Director · 8-K, 2026-09-11
- · In / out: In · Person: Elena Ridloff · Role: Director · 8-K, 2026-08-11
- · In / out: Out · Person: Tamar Howson · Role: Director · 8-K, 2026-07-06
- · In / out: In · Person: Erik Lundgren · Role: Chief Executive Officer · 8-K, 2026-05-27
- · In / out: In · Person: Michael W. Bonney · Role: Chair of the Board · 8-K, 2026-05-19
Changes10
In (appointed)5
Out (departing)3
Latest filing2026-09-11
Immunic, Inc. reported changes in 8 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-31 to 2026-09-11. They name 7 people, with 5 appointments and 3 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Immunic, Inc. files it.
Also on the record for Immunic, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 2, 2026 | Stake report, Schedule 13G/A, by Aberdeen Group plc | 7.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by OrbiMed Advisors LLC | 5.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Commodore Capital LP | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 7.47% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 4.9% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 7% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G, by Laurion Capital Management LP | 6.06% of the class | 5%+ stakes | Source |
| July 16, 2026 | Stake report, Schedule 13G/A, by Aberdeen Group plc | 6.05% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by 683 CAPITAL MANAGEMENT, LLC | 3.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Alyeska Investment Group, L.P. | 4.85% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 5.7% of the class | 5%+ stakes | Source |
| April 17, 2026 | Stake report, Schedule 13G, by Avidity Partners Management LP | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Immunic, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Immunic, Inc. and the records around it.
Immunic, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Company profile and every filing Mar 2026
- Form D filing Mar 2026
- Who owns it
Companies that share a holder
- Laurion Capital Management LP also filed stake reports on 2 other companies: Pyxis Oncology, Inc. (Nov 2026), Rallybio Corp (Aug 2026)
- Avidity Partners Management LP also filed stake reports on 5 other companies: Context Therapeutics Inc. (May 2026), Perspective Therapeutics, Inc. (Mar 2026), Scynexis, Inc. (Feb 2026)
- Soleus Private Equity Fund III, L.P. also filed stake reports on 5 other companies: Prelude Therapeutics Inc (Jul 2026), CALCIMEDICA, INC. (May 2026), Aprea Therapeutics, Inc. (Apr 2026)
Watch Immunic, Inc.
Get an email when Immunic, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Immunic, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Immunic, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immunic, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 34 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-11 | Out | Director | 8-K, 2026-09-11 | ||
| 2026-08-11 | In | Director | 8-K, 2026-08-11 | ||
| 2026-07-06 | Out | Director | 8-K, 2026-07-06 | ||
| 2026-05-27 | In | Chief Executive Officer | 8-K, 2026-05-27 | ||
| 2026-05-19 | In | Chair of the Board | 8-K, 2026-05-19 | ||
| 2026-04-28 | In | Chief Medical Officer | 2026-04-24 | 8-K, 2026-04-28 | |
| 2026-04-28 | Out | Chief Medical Officer | 8-K, 2026-04-28 | ||
| 2026-04-28 | In | 8-K, 2026-04-28 | |||
| 2026-04-10 | Reported | not named in the filing | 8-K, 2026-04-10 | ||
| 2026-03-31 | Reported | not named in the filing | 8-K, 2026-03-31 |
Who leads Immunic, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Duane Nash, departure reported (filed 2026-09-11). No successor is named in these filings.
- Chief Executive Officer: Erik Lundgren, appointed (filed 2026-05-27).
- Chair of the Board: Michael W. Bonney, appointed (filed 2026-05-19).
- Chief Medical Officer: Andreas Muehler, departure reported (filed 2026-04-28). No successor is named in these filings.
Selling to Immunic, Inc.?
New leaders reset buying decisions — get the Full Report on Immunic, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Immunic, Inc. (free up to 3)
Hiring for a seat like this?
Find people with the same kind of experience as the Director at Immunic, Inc., with the record behind each one.
Find candidates like Director at Immunic, Inc.Every change, in the filing's words
Departing: Duane Nash, Director
On September 10, 2026, Dr. Duane Nash resigned as a member of the Board of Directors (the "Board") of Immunic, Inc., a Delaware corporation (the "Company").
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- Dr. Nash's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- The Board and the Company are deeply grateful for Dr. Nash's service, dedication, and contributions to the Company.
- In connection with Dr. Nash's resignation, by resolution of the Board, the size of the Board was reduced from ten members to nine members.
Appointed: Elena Ridloff, Director
On August 6, 2026, the board of directors (the "Board") of the Company appointed Elena Ridloff as a member of the Board, effective immediately.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- As a Class I director, Ms. Ridloff's term lasts until the Company's 2027 annual meeting of stockholders, and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.
- Elena Ridloff, CFA, age 46, has served as a member of the board of directors of Kymera Therapeutics, Inc. since March 2021.
- Ms. Ridloff has served as the Chief Financial Officer of Sionna Therapeutics, Inc., a publicly traded life sciences company, since September 2021.
- Ms. Ridloff previously served as the Executive Vice President and Chief Financial Officer of ACADIA Pharmaceuticals Inc., or ACADIA, a publicly traded pharmaceutical company.
- Ms. Ridloff joined ACADIA in April 2018 as Senior Vice President, Investor Relations, where she led investor and financial communications activities, and served as ACADIA's Chief Financial Officer from October 2018 to September 2021.
- Before ACADIA, Ms. Ridloff held various roles at Alexion Pharmaceuticals, Inc., or Alexion, including Executive Director, Investor Relations from April 2014 to January 2016, and Vice President, Investor Relations from January 2016 to March 2018.
Departing: Tamar Howson, Director
On June 29, 2026, Tamar Howson resigned as a member of the Compensation Committee of the Board of Directors (the " Board ") of Immunic, Inc., a Delaware corporation (the " Company "), and as a member of the Board, as Ms. Howson transitions into retirement.
- Ms. Howson's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- The Board and the Company are deeply grateful for Ms. Howson's service, dedication, and contributions to the Company.
- In connection with Ms. Howson's resignation, on July 5, 2026, following the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Erik Lundgren, the Company's Chief Executive Officer, to serve as a Class II director of the Board until the 2028 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.
- Mr. Lundgren has not been appointed to serve on any committee of the Board.
- Mr. Lundgren will not receive any additional compensation for his service as a director.
Appointed: Erik Lundgren, Chief Executive Officer
On May 22, 2026 (the "Effective Date"), Immunic, Inc. (the "Company") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- Erik Lundgren, age 48, served as Senior Vice President, Commercial Portfolio Organization at Genentech, Inc., a member of the Roche Group, from May 2024 to May 2026, where he led and oversaw the commercial strategy across all therapeutic areas of the company's portfolio.
- Prior to that role, Mr. Lundgren was the General Manager of Roche s.r.o. from April 2021 to May 2024.
- Mr. Lundgren was the Lifecycle Leader for Huntington's disease at Roche from January 2018 to May 2021.
- Prior to that, Mr. Lundgren served in roles of increasing responsibility at Genentech from May 2007 to December 2017, including serving as Senior Marketing Director supporting the launch and commercialization of Ocrevus (ocrelizumab).
- Mr. Lundgren began his career in the consulting industry.
- Mr. Lundgren earned his Bachelor of Arts in Public Policy from Duke University and his Master of Business Administration from Harvard Business School.
- In connection with his appointment as Chief Executive Officer, Mr. Lundgren entered into an employment agreement with the Company, dated as of May 22, 2026 (the "Employment Agreement").
Appointed: Michael W. Bonney, Chair of the Board
Appointment of Michael W. Bonney as Chair of the Board On May 16, 2026 (the "Effective Date"), the board of directors (the "Board") of Immunic, Inc., a Delaware corporation (the "Company") appointed Michael W. Bonney as Chair of the Board, effective immediately.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- Mr. Bonney, age 67, has served as chair of the board of directors of Autolus Therapeutics plc since April 2024.
- He has also served as chair of the board of directors of Santa Ana Bio, Inc. since September 2025 and as the chair of the board of directors of Dunad Therapeutics LTD since 2023.
- He previously served as a director of Alnylam Pharmaceuticals, Inc. from December 2014 to December 2025; as chair of Alnylam from December 2015 to August 2021 and as the company's executive chair from August 2021 to January 2023.
- Mr. Bonney previously served as the chair of the board of directors of Kaleido Biosciences, Inc., a biotechnology company, from June 2017 until August 2021.
- Between August 2018 and October 2020, he served as Kaleido's Executive Chair, and served as Kaleido's Chief Executive Officer from June 2017 until August 2018.
- Mr. Bonney was a Partner at Third Rock Ventures, a healthcare venture firm, from January to July 2016.
- Mr. Bonney previously served as the Chief Executive Officer and a member of the board of directors of Cubist Pharmaceuticals, Inc., or Cubist, a biopharmaceutical company (now a wholly-owned subsidiary of Merck & Co., Inc. ("Merck")), from June 2003 until his retirement in December 2014, coinciding with Cubist's acquisition by Merck for $9.5 billion.
Appointed: Michael A. Panzara, Chief Medical Officer, effective 2026-04-24
Appointment of Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer Effective April 24, 2026 (the "Effective Date"), Immunic, Inc. (the "Company") appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer of the Company, effective immediately.
Departing: Andreas Muehler, Chief Medical Officer
Resignation of Andreas Muehler, M.D., M.B.A. On April 27, 2026, Andreas Muehler, M.D., M.B.A., resigned as the Chief Medical Officer of the Company.
Appointed: Andreas Muehler
Dr. Muehler will serve as Senior Medical Officer through the Separation Date.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- Michael Panzara, M.D., M.P.H., age 59, served as chief medical officer at Neurvati Neurosciences, Inc., a Blackstone Life Sciences portfolio company, from October 2022 to March 2026.
- Previously, Dr. Panzara served as chief medical officer and head of therapeutics discovery and development at Wave Life Sciences Ltd., a publicly traded genetic medicines company, from May 2020 to October 2022, where he previously served as chief medical officer from November 2018 to May 2020 and as franchise lead of neurology from July 2016 to November 2018.
- Prior to joining Wave Life Sciences, Dr. Panzara served in various roles at Sanofi Genzyme, including most recently as head of multiple sclerosis, neurology and ophthalmology therapeutic area for global development.
- Dr. Panzara has held numerous other positions in the healthcare and biopharmaceutical industries, including vice president and chief medical officer in neurology at Biogen, and instructor in neurology at Harvard Medical School with clinical appointments at Brigham & Women's Hospital and Massachusetts General Hospital.
- Dr. Panzara has served on the board of directors of LeonaBio, Inc. since March 2022.
Reported
The Agreement was entered into in connection with the Company's commencement of a search for a new Chief Executive Officer, and Mr. Vitt's potential transition to a "C-Suite" role that is focused on strengthening the Company's scientific strategy and driving portfolio advancement after a new Chief Executive Officer is hired.
- On April 7, 2026, Immunic, Inc. (the "Company") entered into a Retention Bonus Agreement (the "Agreement") with Daniel Vitt, the Company's Chief Executive Officer.
- Pursuant to the Agreement, subject to Mr. Vitt's continued employment with the Company through the ninety-first (91st) day after a new Chief Executive Officer is hired by the Company (the "Retention Date"), Mr. Vitt shall be entitled to receive a retention bonus equal to $670,000, less applicable withholdings and payroll deductions (the "Retention Bonus").
- The Retention Bonus will be paid in one lump sum on the first regularly scheduled pay date after the Retention Date, subject to the terms and conditions of the Agreement.
- If the Company terminates Mr. Vitt's employment without "Cause" (as defined in his employment agreement with the Company dated as of January 1, 2026 (the "U.S. Employment Agreement")) or Mr. Vitt resigns for "Good Reason" (as defined in the U.S. Employment Agreement) prior to the Retention Date, the Company will pay the Retention Bonus within five (5) days of such termination or resignation, as applicable.
Reported
On March 31, 2026, Immunic, Inc., a Delaware corporation (the "Company"), announced the appointment of Jon Congleton as a member of the board of directors (the "Board") of the Company, effective as of March 27, 2026.
- As a Class II director, Mr. Congleton's term lasts until the Company's 2028 annual meeting of stockholders (the "Annual Meeting").
- Mr. Congleton will also act as Chair of the Compensation Committee of the Board.
- Mr. Congleton, age 62, has served as President and Chief Executive Officer and as a member of the board of directors of Mineralys Therapeutics, Inc. ("Mineralys") since November 2020.
- Prior to joining Mineralys, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020.
- Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017.
- Mr. Congleton was previously at Teva Pharmaceutical Industries Ltd. (Teva), where for over 18 years, he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States.
- Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi.
- Mr. Congleton earned a B.S. in marketing from Kansas State University.
Immunic, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Immunic, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.